Albireo granted Orphan Designation by EC for lead product candidate A4250
Albireo Pharma announced the EC has granted orphan designation to lead product candidate A4250, an ileal bile acid transporter inhibitor, for the treatment of biliary atresia, a rare and life-threatening liver disease with no approved pharmacologic treatment option. December 18, 2018